The present invention is directed to a method for the treatment of depression, for example, treatment of resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at single nucleotide polymorphism (SNP) rs4306882. Specifically, the method comprising determining the presence of a G or T allele at rs4306882, and administering a dosing regimen of ketamine or esketamine, wherein the dosing regimen is adjusted to provide a higher dose and/or greater frequency of the ketamine or esketamine to those patients with the G allele (rather than T allele) at the polymorphic site of rs4306882. Further disclosed is a method for predicting whether a patient suffering from depression is genetically predisposed to poorly respond to antidepressants which block the reuptake of monoamine neurotransmitters, comprising genotyping said patient to determine the patient's genotype at SNP rs4306882.
ESKETAMINE FOR USE IN A METHOD FOR THE TREATMENT OF DEPRESSION